Abstract
The conformation and tautomeric structure of (Z)-4-[5-(2,6-difluorobenzyl)-1-(2-fluorobenzyl)-2-oxo-1,2-dihydropyridin-3-yl]-4-hydroxy-2-oxo-N-(2-oxopyrrolidin-1-yl)but-3-enamide, C27H22F3N3O5, in the solid state has been resolved by single-crystal X-ray crystallography. The electron distribution in the molecule was evaluated by refinements with invarioms, aspherical scattering factors by the method of Dittrich et al. [Acta Cryst. (2005), A61, 314–320] that are based on the Hansen–Coppens multipole model [Hansen & Coppens (1978 ▶). Acta Cryst. A34, 909–921]. The β-diketo portion of the molecule exists in the enol form. The enol –OH hydrogen forms a strong asymmetric hydrogen bond with the carbonyl O atom on the β-C atom of the chain. Weak intramolecular hydrogen bonds exist between the weakly acidic α-CH hydrogen of the keto–enol group and the pyridinone carbonyl O atom, and also between the hydrazine N—H group and the carbonyl group in the β-position from the hydrazine N—H group. The electrostatic properties of the molecule were derived from the molecular charge density. The molecule is in a lengthened conformation and the rings of the two benzyl groups are nearly orthogonal. Results from a high-field 1H and 13C NMR correlation spectroscopy study confirm that the same tautomer exists in solution as in the solid state.
Comment
The retroviral enzyme HIV-1 integrase is essential for HIV replication and is a significant target for the discovery and development of anti-HIV therapeutic agents (Moir et al., 2011 ▶; Frankel & Young, 1998 ▶; Nair & Chi, 2007 ▶; Pommier et al., 2005 ▶). Research efforts on anti-HIV integrase inhibitors for the treatment of acquired immunodeficiency syndrome (AIDS) have resulted in several anti-HIV agents, two of which, raltegravir and elvitegravir, have been approved by the US Food and Drug Administration for the clinical treatment of HIV–AIDS (Nair et al., 2006 ▶; Summa et al., 2008 ▶; Min et al., 2010 ▶; Shimura & Kodama, 2009 ▶; Taktakishvili et al., 2000 ▶). The crystallographic structures of some HIV integrase inhibitors have been reported [see, for example, Rhodes et al. (2011 ▶) and Newton et al. (2005 ▶)]. As resistance, toxicity and drug–drug interactions are recurring issues with all classes of anti-HIV drugs, the discovery of new anti-HIV active integrase inhibitors remains a significant scientific challenge. The compound (Z)-4-[5-(2,6-difluorobenzyl)-1-(2-fluorobenzyl)-2-oxo-1,2-dihydropyridin-3-yl]-4-hydroxy-2-oxo-N-(2-oxopyrrolidin-1-yl)but-3-enamide, (1), discovered in our laboratory, is an integrase inhibitor which possesses potent (low nM) anti-HIV activity against a diverse set of HIV-1 isolates and also against HIV-2 and SIV. However, this compound can exist in three possible forms (I, II and III) with respect to the β-diketo functionality (see Scheme 1). In order to determine which tautomeric form is dominant in the solid state, the single-crystal X-ray structure of integrase inhibitor (1) was undertaken. An invariom refinement (Dittrich et al., 2005 ▶; Hansen & Coppens, 1978 ▶) was performed to examine the electrostatic properties of the molecule in further detail.
The molecular structure of (1) contains a variety of distinct groups, including a central pyridinone ring, fluorobenzene rings, a keto–enol group and a 2-oxopyrrolidin-1-yl group (Fig. 1 ▶ and Table 1 ▶). The scattering factors of some fragments were not yet present in the invariom database (Dittrich et al., 2006 ▶) and so were calculated here using quantum mechanics. This method of refinement led to C—H distances somewhat longer [1.013 (15)–1.107 (12) Å] than ordinarily expected from an X-ray determination but closer to distances determined from neutron diffraction (Allen et al., 2006 ▶).
Figure 1.
The molecular structure of the dominant tautomeric form of (1) present in the crystalline state. Displacement ellipsoids are drawn at the 50% probability level. Dashed lines indicate intramolecular hydrogen bonds.
Table 1. Selected geometric parameters (Å, °).
| F36—C24 | 1.3484 (12) |
| F37—C31 | 1.3467 (13) |
| F38—C35 | 1.3444 (13) |
| O8—C7 | 1.2102 (11) |
| O9—C5 | 1.2178 (12) |
| O11—C10 | 1.2678 (11) |
| O14—C13 | 1.3033 (12) |
| O21—C16 | 1.2245 (11) |
| N1—N6 | 1.3802 (11) |
| N1—C2 | 1.4605 (13) |
| N1—C5 | 1.3608 (12) |
| N6—C7 | 1.3531 (13) |
| C7—C10 | 1.5271 (14) |
| C10—C12 | 1.3986 (14) |
| C12—C13 | 1.3979 (14) |
| C12—H12 | 1.038 (12) |
| C13—C15 | 1.4682 (14) |
| C15—C16 | 1.4553 (13) |
| C15—C20 | 1.3784 (13) |
| C18—C19 | 1.3676 (14) |
| C19—C20 | 1.4078 (14) |
| O11—C10—C7 | 117.89 (9) |
| O11—C10—C12 | 125.07 (9) |
| C7—C10—C12 | 117.02 (9) |
| C10—C12—C13 | 119.72 (9) |
| C10—C12—H12 | 120.1 (7) |
| C13—C12—H12 | 120.1 (7) |
| O14—C13—C12 | 120.11 (9) |
| O14—C13—C15 | 116.09 (9) |
| C12—C13—C15 | 123.79 (9) |
The refined position of the H atom in the strong intramolecular O—H⋯O hydrogen bond indicated that it is not symmetrically located between the two O-atom centers but rather favors atom O14 over O11, i.e. form I is the dominant form in the solid. This is reflected by the longer C—O bond for O14 [1.3033 (12) Å, compared with 1.2678 (11) Å for O11]. However, this is not a completely localized H atom and there is some residual disorder. This was seen in the residual electron-density map about atom O11, with a maximum peak height of 0.24 e Å−3 between atoms O11 and H14 (Fig. 2 ▶). A deformation electron-density map (with contour step values of ±0.05 e Å−3) is shown in Fig. 3 ▶. The hydrogen bond is not linear; the O14—H14⋯O11 angle is 155.5 (16)° (Table 2 ▶). The H atom on atom N6 donates an intermolecular hydrogen bond to atom O9i (N6—H6⋯O9i; Table 2 ▶), forming a centrosymmetric dimer. The slightly acidic α-C—H hydrogen of the keto–enol group donates a weak intramolecular hydrogen bond to carbonyl atom O21 (C12—H12⋯O21; Table 2 ▶).
Figure 2.

A residual electron-density map in the plane of the atoms of the keto–enol group. Contours are drawn at 0.05 e Å−3 intervals. Solid lines represent positive contours and dashed lines negative contours.
Figure 3.

A deformation electron-density map in the plane of the atoms of the keto–enol group. Contours are drawn at 0.05 e Å−3 intervals. Solid lines represent positive contours and dashed lines negative contours.
Table 2. Hydrogen-bond geometry (Å, °).
| D—H⋯A | D—H | H⋯A | D⋯A | D—H⋯A |
|---|---|---|---|---|
| N6—H6⋯O9i | 1.000 (14) | 1.924 (14) | 2.8014 (12) | 144.8 (10) |
| O14—H14⋯O11 | 1.092 (18) | 1.492 (18) | 2.5270 (11) | 155.5 (16) |
| C12—H12⋯O21 | 1.038 (13) | 2.135 (12) | 2.8346 (13) | 122.7 (9) |
Symmetry code: (i)
.
Since a complete static electron-density distribution is available from the invariom model scattering factors, various properties like the dipole moment and electrostatic potential [V(r)] can be derived from the electron density. They were calculated using the program XDPROP in XD2006 (Volkov et al., 2006 ▶). The results could provide information on the capacity of this molecule to interact with a protein-binding site. The dipole moment (p) for the molecule calculated from the multipole populations is 12.06 D. The electrostatic field is the force that a hypothetical proton would be subjected to if it were present. The electrostatic potential (a scalar quantity) at a given point can be defined as the amount of work that is needed to bring a unit of charge from infinity to that point. A composite of the positive (0.2 e Å−3) and negative (−0.06 e Å−3) electrostatic potential isosurfaces plotted with the program Molekel (Molekel, 2009 ▶) is shown in Fig. 4 ▶. Regions of strong positive potential are shown in lighter grey and negative potential in dark grey. Atom H14, involved in a strong intramolecular hydrogen bond, shows a strong positive potential, while adjacent atom O11 shows a strong negative potential.
Figure 4.
Positive (0.2 e Å−3) and negative (−0.06 e Å−3) electrostatic potential isosurfaces of (1) shown in light and dark grey, respectively.
The results of a high-field 1H and 13C NMR correlation spectroscopy study (COSY, HSQC, HMQC, HMBC and NOESY) are consistent with the structure observed in the solid state.
Experimental
The integrase inhibitor was prepared from the coupling of the corresponding diketo acid (Seo et al., 2011 ▶) and 1-amino-2-pyrrolidinone p-toluenesulfonate. Compound (1) crystallized from dichloromethane as yellow prisms (yield 78%; m.p. 448–449 K). UV (CH3OH, λ, nm): 401 (∊ 9, 139), 318 (∊ 6, 225). HRMS calculated for C27H22F3N3O5: [M + H]+ 526.1590; found: 526.1589.
Crystal data
C27H22F3N3O5
M r = 525.48
Triclinic,
a = 8.8182 (10) Å
b = 11.5986 (13) Å
c = 12.2741 (14) Å
α = 98.594 (2)°
β = 90.904 (2)°
γ = 106.435 (2)°
V = 1188.3 (2) Å3
Z = 2
Mo Kα radiation
μ = 0.12 mm−1
T = 173 K
0.75 × 0.65 × 0.35 mm
Data collection
Bruker APEXII area-detector diffractometer
Absorption correction: empirical (using intensity measurements) (SADABS; Sheldrick, 2008b ▶) T min = 0.841, T max = 1.000
22962 measured reflections
5447 independent reflections
5175 reflections with I > 3σ(I)
R int = 0.029
Refinement
R[F 2 > 2σ(F 2)] = 0.035
wR(F 2) = 0.067
S = 2.00
5175 reflections
431 parameters
All H-atom parameters refined
Δρmax = 0.24 e Å−3
Δρmin = −0.19 e Å−3
The program InvariomTool (Hübschle et al., 2007 ▶) was used to prepare master and input files for an invariom refinement with the XDLSM program of the XD2006 suite (Volkov et al., 2006 ▶). The program assigns invarioms to all atoms in a given crystal structure by examining the connectivity in terms of nearest or next-nearest neighbors. Nonspherical valence scattering contributions for atoms in an environment of single bonds were obtained from theoretical calculations on model compounds that included nearest-neighbour atoms, whereas for H atoms and atoms in a delocalized chemical environment the model compounds also included the next-nearest neighbor atoms. Several fragments were not present in the invariom database. Therefore, new scattering factors for these fragments, including the keto–enol group, were calculated from geometry optimizations at the B3LYP/D95++(3df,3pd) level of theory and included in the invariom database to increase its coverage of chemical environments. These calculations were performed using GAUSSIAN09 (Frisch et al., 2009 ▶). Full-matrix least-squares refinements on F 2 using complete multipole expansions were carried out with the program XDLSM using statistical weights. Only reflections with intensities I > 3σ(I) were included in the refinement. Initially, bond lengths involving H atoms were set to the X—H distances obtained from model compounds that included the next-nearest neighbors of the H atom of interest. However, in the final cycles, these atom positions were refined freely. Positional and displacement (anisotropic for non-H atoms) parameters, but not multipoles, were refined. However, a hexadecapolar level of the multipole expansion was used for all atoms. A molecular electroneutrality constraint was applied. The introduction of invarioms improved R(F) from 0.0511 to 0.0349 while using the same weighting scheme {w = 1/[σ2(F o 2)]} as the spherical-atom refinement, and improved the goodness-of-fit value from 2.832 to 2.001.
Data collection: APEX2 (Bruker, 2011 ▶); cell refinement: SAINT (Bruker, 2009 ▶); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008a ▶); program(s) used to refine structure: XD2006 (Volkov et al., 2006 ▶); molecular graphics: XD2006, Molekel (Molekel, 2009 ▶) and OLEX2 (Dolomanov et al., 2009 ▶); software used to prepare material for publication: XD2006.
Supplementary Material
Crystal structure: contains datablock(s) global. DOI: 10.1107/S0108270113003806/fn3128sup1.cif
Structure factors: contains datablock(s) 1. DOI: 10.1107/S0108270113003806/fn31281sup2.hkl
Supplementary material file. DOI: 10.1107/S0108270113003806/fn31281sup3.cdx
Supplementary material file. DOI: 10.1107/S0108270113003806/fn31281sup4.cml
Acknowledgments
Support of this research by the US National Institutes of Health (grant Nos. R01 AI 43181 and NCRR S10-RR025444) is gratefully acknowledged. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. VN also acknowledges research support from the Terry Endowed Chair in Drug Discovery and from the Georgia Research Alliance Eminent Scholar Award. JB gratefully acknowledges assistance from Birger Dittrich with using XD2006 and the invariom refinements. The authors acknowledge an NSF MRI-R2 grant (No. CHE-0958205) and the use of the resources of the Cherry L. Emerson Center for Scientific Computation.
Footnotes
Supplementary data for this paper are available from the IUCr electronic archives (Reference: FN3128). Services for accessing these data are described at the back of the journal.
References
- Allen, F. H., Watson, D. G., Brammer, L., Orpen, A. G. & Taylor, R. (2006). Typical interatomic distances: organic compounds, in International Tables for Crystallography, Vol. C, edited by E. Prince, pp. 790–811. Dordrecht: Kluwer Academic Publishers.
- Bruker (2009). SAINT-Plus Bruker AXS Inc., Madison, Wisconsin, USA.
- Bruker (2011). APEX2 Bruker AXS Inc., Madison, Wisconsin, USA.
- Dittrich, B., Hübschle, C. B., Luger, P. & Spackman, M. A. (2006). Acta Cryst. D62, 1325–1335. [DOI] [PubMed]
- Dittrich, B., Hübschle, C. B., Messerschmidt, M., Kalinowski, R., Girnt, D. & Luger, P. (2005). Acta Cryst. A61, 314–320. [DOI] [PubMed]
- Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & Puschmann, H. (2009). J. Appl. Cryst. 42, 339–341.
- Frankel, A. D. & Young, J. A. T. (1998). Annu. Rev. Biochem. 67, 1–25. [DOI] [PubMed]
- Frisch, M. J., et al. (2009). GAUSSIAN09 Gaussian Inc., Wallingford, CT, USA.
- Hansen, N. K. & Coppens, P. (1978). Acta Cryst. A34, 909–921.
- Hübschle, C. B., Luger, P. & Dittrich, B. (2007). J. Appl. Cryst. 40, 623–627.
- Min, S., Song, I., Borland, J., Chen, S., Lou, Y., Fujiwara, T. & Piscitelli, S. C. (2010). Antimicrob. Agents Chemother. 54, 254–258. [DOI] [PMC free article] [PubMed]
- Moir, S., Chun, T. & Fauci, A. (2011). Annu. Rev. Pathol. Mech. Dis. 6, 223–248. [DOI] [PubMed]
- Molekel (2009). Molekel Multiplatform Molecular Visualization, http://cscs.ch/molekel.
- Nair, V. & Chi, G. (2007). Rev. Med. Virol. 17, 277–295. [DOI] [PubMed]
- Nair, V., Chi, G., Ptak, R. & Neamati, N. (2006). J. Med. Chem. 49, 445–447. [DOI] [PMC free article] [PubMed]
- Newton, M. G., Campana, C. F., Chi, G.-C., Lee, D., Liu, Z.-J., Nair, V., Phillips, J., Rose, J. P. & Wang, B.-C. (2005). Acta Cryst. C61, o518–o520. [DOI] [PubMed]
- Pommier, Y., Johnson, A. A. & Marchand, C. (2005). Nat. Rev. Drug Discov. 3, 236–248. [DOI] [PubMed]
- Rhodes, D. I., Peat, T. S., Vandegraaff, N., Jeevarajah, D., Newman, J., Martyn, J., Coates, J. A. V., Ede, N. J., Rea, P. & Deadman, J. J. (2011). ChemBioChem, 12, 2311–2315. [DOI] [PubMed]
- Seo, B. I., Uchil, V. R., Okello, M., Mishra, S., Ma, X., Nishonov, M., Shu, Q., Chi, G. & Nair, V. (2011). ACS Med. Chem. Lett, 2, 877–881. [DOI] [PMC free article] [PubMed]
- Sheldrick, G. M. (2008a). Acta Cryst. A64, 112–122. [DOI] [PubMed]
- Sheldrick, G. M. (2008b). SADABS Bruker AXS Inc., Madison, Wisconsin, USA.
- Shimura, K. & Kodama, E. N. (2009). Antivir. Chem. Chemother. 20, 79–85. [DOI] [PubMed]
- Summa, V. et al. (2008). J. Med. Chem. 51, 5843–5855. [DOI] [PubMed]
- Taktakishvili, M., Neamati, N., Pommier, Y., Pal, S. & Nair, V. (2000). J. Am. Chem. Soc. 122, 5671–5677.
- Volkov, A., Macchi, P., Farrugia, L. J., Gatti, C., Mallinson, P., Richter, T. & Koritsanszky, T. (2006). XD2006 Middle Tennessee State University, USA, Università di Milano and CNR–ISTM Milano, Italy, University of Glasgow, Scotland, State University of New York at Buffalo, USA, and Freie Universität Berlin, Germany.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Crystal structure: contains datablock(s) global. DOI: 10.1107/S0108270113003806/fn3128sup1.cif
Structure factors: contains datablock(s) 1. DOI: 10.1107/S0108270113003806/fn31281sup2.hkl
Supplementary material file. DOI: 10.1107/S0108270113003806/fn31281sup3.cdx
Supplementary material file. DOI: 10.1107/S0108270113003806/fn31281sup4.cml


